Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 20, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Apremilast in the Treatment of Moderate to Severe Acne

NCT01074502
View directory record Official record
Conditions
Acne
Interventions
apremilast
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 20, 2026, 4:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AV-23-001 AVAVA MIRIA Pilot Study

NCT06557434
View directory record Official record
Conditions
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity, Scars
Interventions
MIRIA
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Dix Hills, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

NCT04724473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Cream 0.025%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,030 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

NCT07013747
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Encino, California • Brandon, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

NCT03767400
View directory record Official record
Conditions
Skin Care
Interventions
Skin Imaging, Facial Cleanser
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

NCT03681470
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Aczone Gel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00422240
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%, Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

NCT03168321
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, IDP-123 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
42
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • La Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AVAVA MIRIA General Use

NCT06868615
View directory record Official record
Conditions
Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle, Pigment; Lesion, Skin Texture Disorder
Interventions
AVAVA
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

NCT02661958
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Acleara Needle Insert on Acne

NCT01677221
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acleara Acne Treatment System
Device
Lead sponsor
Theravant Corporation
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
White Plains, Maryland • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 20, 2026, 4:46 PM EDT
Not listed Not applicable Interventional

Self-Administered Intralesional Injections for Acne

NCT06186596
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Triamcinolone delivered via injection assistance device
Device
Lead sponsor
ACOM Labs
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Fremont, California • Boca Raton, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 20, 2026, 4:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

NCT05942248
View directory record Official record
Conditions
Acne, Melasma, Rosacea, Seborrheic Dermatitis
Interventions
No Intervention
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

NCT04856917
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Imsidolimab, Placebo
Drug · Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 45 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Sherman Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational

Wound Etiology and Healing Study

NCT01352078
View directory record Official record
Conditions
Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 4:46 PM EDT
Not listed Not applicable Interventional

Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars

NCT04807179
View directory record Official record
Conditions
Acne Scars
Interventions
Experimental: RF Device Arm
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

NCT01885910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 100mg, Aczone 5% gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 20, 2026, 4:46 PM EDT